Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.

Roberta S Azevedo, Julie Braish, Georgina Gener-Ricos, Guilin Tang, Koji Sasaki, Guillermo Montalban-Bravo, Elias Jabbour, Maro Ohanian, Musa Yilmaz, Fadi G Haddad, Kelly Chien, Jo Ishizawa, Nicholas J Short, Abhishek Maiti, Mahesh Swaminathan